Active Deal-Making Year Anticipated In HCV As New, Better Drug Combos Emerge
Executive Summary
Following the European Association for the Study of the Liver's annual meeting this past week in Vienna, Austria, it became clear that most companies active in the hepatitis C space hope to be part of the current best hope for HCV therapy: a once-daily, oral cocktail of antiviral drugs that will replace the current standard of care
You may also be interested in...
Bristol, Pharmasset To Study Oral HCV Regimen Together
Partnership to study Bristol's NS5A inhibitor with Pharmasset's polymerase inhibitor is the first cross-company collaboration to study two oral agents in hepatitis C.
Idenix Clinical Hold On Two Hep C Programs May Be Resolved By Year-End
Serious adverse events that triggered an FDA clinical hold on two of Idenix's hepatitis C programs - IDX184 and IDX320 - could have been caused by an unforeseen effect of combining the drugs, as opposed to a defect with one of the individual drugs
Idenix Clinical Hold On Two Hep C Programs May Be Resolved By Year-End
Serious adverse events that triggered an FDA clinical hold on two of Idenix's hepatitis C programs - IDX184 and IDX320 - could have been caused by an unforeseen effect of combining the drugs, as opposed to a defect with one of the individual drugs